Myotonic dystrophy type 1 is a rare, dominantly inherited, progressive, disabling, neuromuscular disease that leads to decreased life expectancy and has no approved therapies. The disease is caused by ...

REDWOOD CITY, Calif., Jan. 7, 2026 /PRNewswire/ -- Codexis, Inc. (CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing and Axolabs, part of LGC Group, ...

RNA-based medicines are transforming the way we treat disease—offering targeted, precision therapies for conditions ranging from rare genetic disorders to widespread chronic illnesses like diabetes, ...

The Pixar Era kicked off 30 years ago with the first installment of the popular franchise. It’s given us countless hits, but something has also been lost. By Maya Phillips There are so many ways of ...

The global DNA Synthesis market size is forecasted to reach around USD 30,320 million by 2034, increasing from USD 4,980 million in 2024 and representing a remarkable CAGR of 19.8% from 2025 to 2034.

In today’s competitive biotechnology landscape, control and speed define success for companies and core labs producing synthetic genes. Yet many gene synthesis teams still rely on outsourced oligo ...

Despite today’s biological sophistication behind antibody discovery, many bottlenecks remain. According to Paul DiGregorio, PhD, head of commercial strategy and partnerships at Telesis Bio, the ...

Therapeutic oligonucleotides (ONs) offer promising treatments for conditions beyond what traditional therapies can target. As a new class of molecules, they demand precise characterization in both ...